|
|
|
Insider
Information: |
Sonsini Peter W. |
Relationship: |
10% Owner |
City: |
Menlo Park |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
39 |
|
Direct
Shares |
66,219,175 |
|
Indirect Shares
|
287,129,918 |
|
|
Direct
Value |
$484,917,870 |
|
|
Indirect Value
|
$554,586,967 |
|
|
Total
Shares |
353,349,093 |
|
|
Total
Value |
$1,039,504,837 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
5
|
0
|
Stock
price went up :
|
2
|
0
|
Stock
price went down : |
3
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
21.6%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Interleukin Genetics Inc |
ILIU |
10% Owner |
|
0 |
2016-07-29 |
55,418,811 |
Premium* |
|
Loxo Oncology, Inc. |
LOXO |
10% Owner |
2014-08-06 |
0 |
2014-08-06 |
1,789,420 |
Premium* |
|
Tracon Pharmaceuticals, Inc. |
TCON |
10% Owner |
2015-02-04 |
0 |
2016-11-29 |
2,758,039 |
Premium* |
|
Champions Biotechnology Inc |
CSBR |
10% Owner |
|
0 |
2015-03-11 |
18,750,000 |
Premium* |
|
Ardelyx Inc |
ARDX |
10% Owner |
|
0 |
2019-12-09 |
6,564,372 |
Premium* |
|
Nuvelo Inc |
ABIO |
10% Owner |
|
0 |
2018-02-26 |
0 |
Premium* |
|
Synlogic Inc |
SYBX |
10% Owner |
2015-10-05 |
0 |
2018-01-26 |
4,228,940 |
Premium* |
|
Avalo Therapeutics, Inc |
AVTX |
10% Owner |
2015-10-20 |
0 |
2015-10-20 |
594,245 |
Premium* |
|
Adaptimmune Therapeutics PLC |
ADAP |
10% Owner |
|
0 |
2020-01-24 |
102,478,668 |
Premium* |
|
Aveo Pharmaceuticals Inc |
AVEO |
10% Owner |
|
0 |
2022-10-19 |
24 |
Premium* |
|
Achaogen Inc |
AKAO |
10% Owner |
|
0 |
2016-12-19 |
5,215,128 |
Premium* |
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
|
0 |
2018-03-09 |
0 |
Premium* |
|
Mulesoft, Inc |
MULE |
10% Owner |
|
0 |
2018-05-01 |
0 |
Premium* |
|
Mersana Therapeutics, Inc. |
MRSN |
10% Owner |
2020-09-14 |
745 |
2020-09-14 |
596 |
Premium* |
|
Regulus Therapeutics Inc. |
RGLS |
10% Owner |
|
0 |
2020-12-04 |
6,451,056 |
Premium* |
|
Surface Oncology, Inc. |
SURF |
10% Owner |
2020-05-20 |
2,892,877 |
2018-04-23 |
3,312,877 |
Premium* |
|
Appian Corp |
APPN |
10% Owner |
2018-02-13 |
339 |
2018-02-13 |
676 |
Premium* |
|
Genocea Biosciences, Inc. |
GNCA |
10% Owner |
2019-02-14 |
0 |
2022-05-25 |
0 |
Premium* |
|
Trevi Therapeutics, Inc. |
TRVI |
10% Owner |
2019-05-09 |
0 |
2022-04-11 |
948,948 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
0 |
2019-07-22 |
4,186,243 |
Premium* |
|
Akouos, Inc. |
AKUS |
10% Owner |
2020-06-30 |
0 |
2022-11-30 |
0 |
Premium* |
|
Nkarta, Inc. |
NKTX |
10% Owner |
2020-07-14 |
0 |
2020-07-14 |
2,902,115 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
2,437,689 |
Premium* |
|
Metacrine, Inc. |
MTCR |
10% Owner |
2020-09-18 |
0 |
2021-12-22 |
2,563,257 |
Premium* |
|
Eargo, Inc. |
EAR |
10% Owner |
2020-10-20 |
0 |
2021-05-24 |
821 |
Premium* |
|
Desktop Metal Ord Shs Class A |
DM |
10% Owner |
|
0 |
2021-06-08 |
54 |
Premium* |
|
Savara Inc |
SVRA |
10% Owner |
|
0 |
2021-03-15 |
24,137,931 |
Premium* |
|
Marker Therapeutics Inc |
MRKR |
10% Owner |
2021-03-16 |
0 |
2021-03-16 |
10,714,285 |
Premium* |
|
Reneo Pharmaceuticals, Inc. |
RPHM |
10% Owner |
2021-04-13 |
4,785,494 |
2021-04-13 |
0 |
Premium* |
|
Bright Health Group Inc. |
BHG |
10% Owner |
|
0 |
2021-06-28 |
23,983,073 |
Premium* |
|
Monte Rosa Therapeutics, Inc. |
GLUE |
10% Owner |
2021-06-28 |
0 |
2021-06-28 |
7,692,298 |
Premium* |
|
Robinhood Markets, Inc. |
HOOD |
Director |
2021-08-02 |
0 |
2022-05-02 |
270 |
Premium* |
|
Ionq Ord Shs |
IONQ |
10% Owner |
2022-05-31 |
26,306,693 |
2022-11-16 |
70 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
10% Owner |
2022-01-25 |
3,305,601 |
2021-12-27 |
0 |
Premium* |
|
Casper Sleep Inc. |
CSPR |
10% Owner |
2022-01-25 |
0 |
2022-01-25 |
0 |
Premium* |
|
Arcellx, Inc. |
ACLX |
10% Owner |
2022-02-08 |
6,432,762 |
2022-12-20 |
12 |
Premium* |
|
Senti Biosciences, Inc |
SNTI |
10% Owner |
2022-06-08 |
4,426,151 |
|
0 |
Premium* |
|
Zerofox Holdings Ord Shs |
ZFOX |
10% Owner |
2022-08-03 |
18,068,513 |
|
0 |
Premium* |
|
Oyster Point Pharma, Inc. |
OYST |
10% Owner |
2023-01-03 |
0 |
2023-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
APPN |
Appian Corp |
10% Owner |
|
2017-11-20 |
4 |
S |
$19.49 |
$54,971,857 |
I/I |
(2,820,516) |
0 |
0 |
- |
|
APPN |
Appian Corp |
10% Owner |
|
2017-11-27 |
4 |
S |
$19.49 |
$11,101,894 |
I/I |
(569,620) |
0 |
0 |
- |
|
ABIO |
Nuvelo Inc |
10% Owner |
|
2018-02-26 |
4 |
S |
$0.50 |
$731,273 |
I/I |
(1,460,209) |
0 |
0 |
- |
|
TRVI |
Trevi Therapeutics, Inc. |
10% Owner |
|
2020-04-03 |
4 |
S |
$2.66 |
$1,500 |
I/I |
(564) |
5,937,998 |
0 |
- |
|
SURF |
Surface Oncology, Inc. |
10% Owner |
|
2020-05-20 |
4 |
S |
$3.66 |
$1,535,562 |
D/D |
(420,000) |
2,892,877 |
0 |
% |
|
MTCR |
Metacrine, Inc. |
10% Owner |
|
2021-12-10 |
4 |
S |
$1.32 |
$49,630 |
I/I |
(37,570) |
3,022,957 |
0 |
- |
|
MTCR |
Metacrine, Inc. |
10% Owner |
|
2021-12-22 |
4 |
S |
$0.91 |
$444,853 |
I/I |
(459,700) |
2,563,257 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2021-12-27 |
4 |
S |
$2.42 |
$67,007 |
D/D |
(27,651) |
3,695,192 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2021-12-28 |
4 |
S |
$2.34 |
$57,539 |
D/D |
(24,580) |
3,670,612 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2021-12-29 |
4 |
S |
$2.30 |
$34,954 |
D/D |
(15,196) |
3,655,416 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-07 |
4 |
S |
$2.08 |
$30,318 |
D/D |
(14,600) |
3,492,424 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-10 |
4 |
S |
$2.00 |
$3,502 |
D/D |
(1,751) |
3,490,673 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-11 |
4 |
S |
$2.04 |
$4,919 |
D/D |
(2,409) |
3,488,264 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-12 |
4 |
S |
$2.02 |
$9,357 |
D/D |
(4,634) |
3,483,630 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-13 |
4 |
S |
$1.93 |
$13,886 |
D/D |
(7,209) |
3,476,421 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-14 |
4 |
S |
$1.91 |
$18,583 |
D/D |
(9,707) |
3,466,714 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-18 |
4 |
S |
$1.89 |
$12,927 |
D/D |
(6,848) |
3,459,866 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-19 |
4 |
S |
$1.82 |
$24,414 |
D/D |
(13,412) |
3,446,454 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-20 |
4 |
S |
$1.81 |
$11,385 |
D/D |
(6,295) |
3,440,159 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-21 |
4 |
S |
$1.67 |
$19,389 |
D/D |
(11,622) |
3,428,537 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-24 |
4 |
S |
$1.55 |
$31,017 |
D/D |
(19,984) |
3,408,553 |
0 |
- |
|
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2022-01-25 |
4 |
S |
$1.47 |
$151,803 |
D/D |
(102,952) |
3,305,601 |
0 |
- |
|
GNCA |
Genocea Biosciences, Inc. |
10% Owner |
|
2022-05-24 |
4 |
S |
$0.07 |
$387,943 |
I/I |
(5,931,843) |
4,445,093 |
0 |
- |
|
GNCA |
Genocea Biosciences, Inc. |
10% Owner |
|
2022-05-25 |
4 |
S |
$0.08 |
$362,720 |
I/I |
(4,445,093) |
0 |
0 |
- |
|
IONQ |
Ionq Ord Shs |
10% Owner |
|
2022-05-26 |
4 |
S |
$5.80 |
$5,377,726 |
D/D |
(926,619) |
28,303,040 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|